R
Robert Löfberg
Researcher at Karolinska Institutet
Publications - 159
Citations - 10763
Robert Löfberg is an academic researcher from Karolinska Institutet. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 53, co-authored 159 publications receiving 10336 citations. Previous affiliations of Robert Löfberg include Karolinska University Hospital & Sophiahemmet Hospital.
Papers
More filters
Journal ArticleDOI
A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
William J. Sandborn,Brian G. Feagan,Stephen B. Hanauer,Herbert Lochs,Robert Löfberg,Robert Modigliani,Daniel H. Present,Paul Rutgeerts,Jürgen Schölmerich,Eduard F. Stange,Lloyd R. Sutherland +10 more
TL;DR: This work aims to provide a database of clinical trials conducted in patients with Crohn’s and Colitis over a 12-month period and to establish a baseline for evaluating the safety and effectiveness of these studies.
Journal ArticleDOI
A comparison of budesonide with prednisolone for active Crohn's disease
Paul Rutgeerts,Robert Löfberg,H Malchow,Cornelis B.H.W. Lamers,G Olaison,Derek P. Jewell,A Danielsson,H Goebell,O. Østergaard Thomsen,H Lorenz-Meyer +9 more
TL;DR: In this trial, prednisolone reduced scores on the Crohn's disease activity index more, whereas with budesonide there were fewer glucocorticoid-associated side effects and less suppression of pituitary-adrenal function.
Journal ArticleDOI
Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres.
S. N. Gyde,P Prior,R N Allan,A Stevens,Derek P. Jewell,S. C. Truelove,Robert Löfberg,Olle Broström,Göran Hellers +8 more
TL;DR: It is suggested that extensive colitis patients have a genetic predisposition to colorectal cancer and that longstanding inflammation is not of primary importance in the initiation/promotion of cancer in this disease.
Journal ArticleDOI
Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
TL;DR: It is demonstrated not only that patients with PSC and UC have a significantly higher risk of developing colorectal neoplasia compared with patients having UC only, but also that Patients with P SC and UC having coloreCTal neoperasia are more prone to develop cholangiocarcinoma.
Journal ArticleDOI
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response
Geert R. D'Haens,Remo Panaccione,Peter D.R. Higgins,Severine Vermeire,Miquel A. Gassull,Yehuda Chowers,Stephen B. Hanauer,Hans H Herfarth,Daan W. Hommes,Michael A. Kamm,Michael A. Kamm,Robert Löfberg,A. Quary,Bruce E. Sands,Ajit Sood,G. Watermayer,Bret A. Lashner,Marc Lémann,Scott E. Plevy,Walter Reinisch,Stefan Schreiber,Corey A. Siegel,S. R. Targan,Mamoru Watanabe,Brian G. Feagan,William J. Sandborn,Jean-Frederic Colombel,Simon Travis +27 more
TL;DR: Preliminary evidence suggests that a substantial proportion of patients in clinical remission for >1 year, without signs of active inflammation can remain in remission after stopping treatment, and there are insufficient data to make recommendations on when to stop anti-TNF therapy.